Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.  Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. …

Therapeutic Use of Cannabis and Cannabinoids.  Walter KL.  JAMA. Published online August 06, 2026. doi:10.1001/jama.2026.12754 (Patient Information) https://jamanetwork.com/journals/jama/fullarticle/2852547

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition? Lintzeris N, Mills L. Addiction. 2026. doi.org/10.1111/add.70559 https://online…

Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial.  Roepke, S., Schoofs, N., Priebe, K. et al.  Nat Med (2026). doi.org/10.1038/s41591-026-04546-9 https://www.nature.com/articles/s41591-026-04546…

Sleep Disturbance in Opioid Use Disorder: Systematic Review of Insomnia Prevalence and Sedative-Hypnotic Utilization.  Chekani, F., Lu, Y., Jain, A., & Sharma, S. (2026).  Substance Use & Misuse, 1–12. doi.org/10.1080/10826084.20…

Synthetische Cathinone: Was Substitutionsärzte über die neue Generation stimulierender NPS wissen sollten Wenn über Neue Psychoaktive Substanzen (NPS) gesprochen wird, stehen derzeit meist synthetische Opioide wie Fentanyl oder Nitazene im Mittelpu…